Effectiveness of Trolamine in Preventing Radiotherapy-Related Skin Toxicity in Breast Cancer: A Meta-Analysis and Trial Sequential Analysis Study of Randomized Controlled Trials.
Adv Skin Wound CareJun 9, 2026 (epub)
Lufeng Xie, Yu Zeng, Binbin Zhang et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the effectiveness of trolamine in preventing radiotherapy-related skin toxicity in 980 breast cancer patients across 10 randomized controlled trials. The study found that trolamine significantly reduced the incidence of grade 2 or higher skin toxicity, with a relative risk of 0.37 for grade 3 or higher toxicity (95% CI [0.23, 0.62]; P = .0001).
Key findings
- Trolamine increased the incidence of grade 0 to 1 skin toxicity (RR = 1.89; P = .03).
- The incidence of grade 2 skin toxicity was significantly lower with trolamine (RR = 0.51; P = .04).
- Trolamine reduced grade 2 or higher skin toxicity (RR = 0.52; P = .01).
- The incidence of grade 3 or higher skin toxicity was significantly lower (RR = 0.37; P = .0001).
Why it matters
Managing skin toxicity is crucial for improving the quality of life in breast cancer patients undergoing radiotherapy. This study suggests that trolamine may be an effective option for reducing severe skin reactions.